STUDY OF NINE CASES OF Α-Fetoprotein (AFP) PRODUCTING GASTRIC CANCER

Nishio, Yukio; Urakawa, Tomoaki; Nakamoto, Mitsuharu; Yamaguchi, Toshimasa; Tanaka, Hiroaki; Idei, Hideki; Noshi, Tamotsu; Iso, Atsunori; Uematsu, Kiyoshi; Iyoroi, A.; Setoh, Kouichi

doi:10.3919/ringe1963.50.1176

Cited by 9 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The stomach is one of the most common sites affected by these tumors, and the first such case was described by Bourreille et al in 1970 [15]. The reported incidence of AFP-producing gastric carcinoma has been 1.3%-15% of all gastric carcinomas [16][17][18][19][20]. Kodama et al [21] described two histologic types of AFP-producing gastric carcinoma, based on immunohistochemical staining; a medullary type, characterized by polygonal cells arranged in solid nests or sheets, with scattered large pleomorphic or multinucleated giant cells, and a well differentiated papillary or tubular type with clear cytoplasm.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, AFP-producing tumors have been reported in several different organs [7][8][9][10][11][12][13], with gastric adenocarcinoma being one of the most common of these tumors [14]. Since the first report of AFPproducing gastric carcinoma by Bourreille et al [15], other cases have been described, and the incidence is reported to be 1.3%-15% of all gastric carcinomas [16][17][18][19][20]. Kodama et al [21] described two histologic types of AFP-producing gastric carcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatoid adenocarcinoma of the stomach

et al. 2001

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Hepatoid adenocarcinoma of the stomach

et al. 2001

View full text Add to dashboard Cite

“…AFP-GC was first reported in 1970 by Bourreille (14). The incidence of AFP-GC in all gastric carcinoma ranges between 1.3-15.0% (15)(16)(17)(18)(19).…”

Section: Discussionmentioning

confidence: 99%

“…AFP-producing gastric cancer (AFP-GC) was first reported in 1970 by Bourreille (14). The incidence of AFP-GC in all gastric carcinoma ranges between 1.3-15.0% (15)(16)(17)(18)(19). Nagai et al proposed that the defining diagnosis of AFP-GC may be based on the recognition of characteristic histological features (20).…”

Section: Introductionmentioning

confidence: 99%

α-fetoprotein-producing gastric carcinoma: A case report of a rare subtype and literature review

Sun

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. α-fetoprotein (AFP)-producing gastric carcinoma is a rare type of gastric cancer, and the characteristics have not yet been fully elucidated. The present study reports the case of a patient with this type of gastric cancer. A 66-year-old male was referred to the Department of Gastrointestinal Surgery, Qianfoshan Hospital, Shandong University (Jinan, China) with a 20-day history of retrosternal pain. A computed tomography (CT) scan revealed a thickening of the wall of the cardia and massive lymph node swelling in the region of the lesser curvature of the stomach. A laboratory investigation revealed that the serum AFP levels of the patient were elevated to 46.49 ng/ml (normal level, <12.00 ng/ml), and the serum carcinoembryonic antigen (CEA) levels were 382.22 ng/ml (normal range, <5.00 ng/ml). An endoscopy revealed an elevated tumor and AFP-producing gastric cancer was diagnosed. As the tumor was surgically unresectable, the patient received systemic adjuvant chemotherapy [consisting of 1 cycle of oxaliplatin (150 mg; day 1)-fluorouracil(1.0 g; days 2-6)-calcium folinate (0.3 g; days 2-6), 4 cycles of paclitaxel (80 mg; day 1 and 8, repeated day 21) and capecitabine (1,000 g/m 2 , twice daily; days 1-14, repeated day 21), and 2 cycles of oxaliplatin (130 mg/m 2 ; day 1, repeated day 21) and S-1 (100 mg/d; day 1-day 14; repeated day 21)]. During the chemotherapy intermission, the patient experienced partial remission; the serum AFP levels remained between 44.5 and 32.7 ng/ml, and serum CEA levels decreased to a normal level. The CT scan revealed that the enlarged lymph nodes of the patient had decreased in size. During the preoperative examinations, an abdominal CT scan revealed no metastasis to the liver. A radical gastrectomy was performed on October 20, 2014. Additionally, the tumor did not demonstrate the diffusion of AFP. The histopathological examination revealed a poorly differentiated adenocarcinoma, with local and neuroendocrine differentiation and no hepatoid features. According to these histopathological findings, the tumor was diagnosed as AFP-producing non-hepatoid adenocarcinoma of the stomach. The patient was treated with systemic immunity-enhancing therapy and has been free of recurrence for 2 months. The present study describes a rare case of AFP-producing non-hepatoid adenocarcinoma of the stomach, with a review of the literature and an investigation of the clinical features. Introductionα-fetoprotein (AFP) is an oncofetal glycoprotein that is mainly produced by the yolk sac and liver during fetal development, and to a lesser extent, in the fetal gastrointestinal tract (1,2). The greatest serum AFP levels are observed between 12-15 weeks after birth, which decrease to normal adult levels subsequent to approximately one year (3,4). AFP is detected in the serum of adults with hepatocellular carcinoma, yolk sac tumors and noncancerous liver disease (2-6). Rising AFP levels may also be detected in the malignant tumors of various organs, including the stomach, lung, pancreas, colon, bladder ...

show abstract

“…The incidence of AFP-positive gastric cancer is reported to be 1.3-15% overall [21][22][23][24][25] and 2.1% in early gastric cancer [26]. Webb et al described that AFPpositivity is not a poor prognostic factor for advanced gastric cancer [27].…”

Section: Figmentioning

confidence: 99%